Business Context and Reporting Period
BioRestorative Therapies, Inc. filed this Form 8-K on March 24, 2014, to report the entry into a material definitive agreement. The Company is a Nevada corporation headquartered in Jupiter, Florida.
Key Financial Metrics
This filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the new agreement:
- Initial Payment: $250,000
- Additional Potential Payment: Up to $525,000
- Total Potential Value: Up to $775,000 over a two-year term
Material Changes
The material change reported is the execution of a Research Agreement with Pfizer Inc. on March 24, 2014. Under this agreement, the Company will provide research and development services regarding brown fat. No prior comparable period data is provided in this specific filing.
Guidance, Outlook, and Risks
The filing outlines a two-year term for the research services. It does not contain forward-looking guidance, management commentary on future performance, specific risk factors, or contingencies beyond the terms of the agreement itself.
Investor Verification Checklist
- Verify the conditions required to earn the additional $525,000 payment.
- Confirm the specific milestones or deliverables defined in the Research Agreement with Pfizer Inc.
- Review the Company's most recent 10-K or 10-Q for current liquidity and cash position to assess the impact of the initial $250,000 payment.
- Check for any subsequent filings regarding the status of the brown fat research project.